HR 1672 · 119th Congress · Health

Maintaining Investments in New Innovation Act

Introduced 2025-02-27· Sponsored by Rep. Davis, Donald G. [D-NC-1]· House

Bill Progress

✓
Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.(2025-02-27)

Plain Language Summary

[AI summary unavailable — showing source text] Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (20)

3 Democrats17 Republicans
Rep. Joyce, John [R-PA-13]PA
Rep. Gottheimer, Josh [D-NJ-5]NJ
Rep. Tenney, Claudia [R-NY-24]NY
Rep. Yakym, Rudy [R-IN-2]IN
Rep. Morelle, Joseph D. [D-NY-25]NY
Rep. Hudson, Richard [R-NC-9]NC
Rep. Bean, Aaron [R-FL-4]FL
Rep. Miller-Meeks, Mariannette [R-IA-1]IA
Rep. Allen, Rick W. [R-GA-12]GA
Rep. Van Duyne, Beth [R-TX-24]TX
Rep. Peters, Scott H. [D-CA-50]CA
Rep. Moore, Blake D. [R-UT-1]UT
Rep. Crenshaw, Dan [R-TX-2]TX
Rep. Dunn, Neal P. [R-FL-2]FL
Rep. Hern, Kevin [R-OK-1]OK
Rep. Carey, Mike [R-OH-15]OH
Rep. Shreve, Jefferson [R-IN-6]IN
Rep. Pfluger, August [R-TX-11]TX
Rep. Sessions, Pete [R-TX-17]TX
Rep. McDowell, Addison P. [R-NC-6]NC